argenx SE (ARGX.BR)

EUR 610.0

(1.77%)

Total Debt Summary of argenx SE

  • argenx SE's latest annual total debt in 2023 was 18.1 Million EUR , up 45.7% from previous year.
  • argenx SE's latest quarterly total debt in 2024 Q2 was 33.96 Million EUR , down 0.0% from previous quarter.
  • argenx SE reported annual total debt of 12.42 Million USD in 2022, up 8.38% from previous year.
  • argenx SE reported annual total debt of 11.46 Million USD in 2021, up 18.47% from previous year.
  • argenx SE reported quarterly total debt of 33.96 Million EUR for 2024 Q2, down 0.0% from previous quarter.
  • argenx SE reported quarterly total debt of - USD for 2023 Q3, down -100.0% from previous quarter.

Annual Total Debt Chart of argenx SE (2023 - 2010)

Historical Annual Total Debt of argenx SE (2023 - 2010)

Year Total Debt Total Debt Growth
2023 18.1 Million EUR 45.7%
2022 12.42 Million USD 8.38%
2021 11.46 Million USD 18.47%
2020 9.67 Million EUR 32.62%
2019 7.29 Million EUR 0.0%
2018 - EUR 0.0%
2017 - EUR 0.0%
2016 - EUR 0.0%
2015 - EUR 0.0%
2014 - EUR 0.0%
2013 - EUR -100.0%
2012 2.23 Million EUR 2.04%
2011 2.19 Million EUR 0.0%
2010 - EUR 0.0%

Peer Total Debt Comparison of argenx SE

Name Total Debt Total Debt Difference
ABIONYX Pharma SA 3.39 Million EUR -434.079%
ABIVAX Société Anonyme 55.46 Million EUR 67.357%
Adocia SA 13.08 Million EUR -38.335%
Aelis Farma SA 4.03 Million EUR -348.373%
Biophytis S.A. 8.27 Million EUR -118.927%
Advicenne S.A. 17.42 Million EUR -3.904%
genOway Société anonyme 7.23 Million EUR -150.301%
IntegraGen SA 1.12 Million EUR -1509.738%
Medesis Pharma S.A. 1.2 Million EUR -1408.774%
Neovacs S.A. 650 Thousand EUR -2685.428%
NFL Biosciences SA 62.17 Thousand EUR -29020.343%
Plant Advanced Technologies SA 4.35 Million EUR -315.592%
Quantum Genomics Société Anonyme 2.71 Million EUR -566.41%
Sensorion SA 2.86 Million EUR -531.113%
Theranexus Société Anonyme 3.64 Million EUR -396.985%
TME Pharma N.V. 1.16 Million EUR -1452.769%
Valbiotis SA 6.87 Million EUR -163.235%
TheraVet SA 1.15 Million EUR -1460.979%
Valerio Therapeutics Société anonyme 8.99 Million EUR -101.215%
BioSenic S.A. 28.16 Million EUR 35.708%
Celyad Oncology SA 902 Thousand EUR -1907.237%
DBV Technologies S.A. 13.01 Million USD -39.072%
Galapagos NV 9.59 Million EUR -88.675%
Genfit S.A. 70.17 Million EUR 74.201%
GeNeuro SA 7.73 Million EUR -133.985%
Hyloris Pharmaceuticals SA 5.29 Million EUR -241.996%
Innate Pharma S.A. 39.89 Million EUR 54.615%
Inventiva S.A. 37.4 Million EUR 51.599%
MaaT Pharma SA 14.07 Million EUR -28.634%
MedinCell S.A. 58.96 Million EUR 69.293%
Nanobiotix S.A. 50.56 Million EUR 64.194%
Onward Medical N.V. 16.87 Million EUR -7.297%
Oryzon Genomics S.A. 13.68 Million EUR -32.278%
OSE Immunotherapeutics SA 45.8 Million EUR 60.47%
Oxurion NV 12.33 Million EUR -46.792%
Pharming Group N.V. 155.29 Million EUR 88.341%
Poxel S.A. 46.9 Million EUR 61.396%
GenSight Biologics S.A. 18.42 Million EUR 1.751%
Transgene SA 1.25 Million EUR -1340.357%
Financière de Tubize SA 79.2 Million EUR 77.14%
UCB SA 3.03 Billion EUR 99.404%
Valneva SE 208.81 Million EUR 91.33%
Vivoryon Therapeutics N.V. 38 Thousand EUR -47545.479%